# Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure

> **NCT01218464** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Liver Failure
- Mesenchymal Stem Cells

## Interventions

- **DRUG:** Conventional plus MSC treatment
- **DRUG:** Conventional plus pacebo treatment

## Key facts

- **NCT ID:** NCT01218464
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2013-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218464, "Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01218464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*